Safety & efficacy of sotorasib + panitumumab & FOLFIRI for previously treated KRAS G12C-mutated metastatic CRC in the CodeBreaK 101 ph Ib study in @ESMO_Open. 50% G3 or higher TRAEs (mainly skin tox & WBC decrease), ORR 56.5%, mPFS & mOS 8.3 & 17.9 months. esmoopen.com/article/S2059-7…

HER2DX in early-stage HER2-positive BC: a review of clinical utility in @ESMO_Open. Genomic-clinical test with providing prognostic relapse risk score, pCR score, ERBB2 mRNA expression score. Potential support for individualized Tx discussion. esmoopen.com/article/S2059-7…

MYC rearrangement improves the predictive efficacy of the double-hit model in newly diagnosed multiple myeloma in @ESMO_Open. MYC-R is poor prognostic marker and refines the double-hit risk model, while gain/amp may be a high risk factor, esmoopen.com/article/S2059-7…

Final analysis of the FeDeriCa ph III study: long-term efficacy, safety & PKs of the fixed-dose combination of pertuzumab & trastuzumab for s.c. injection, plus CT in HER2+ early BC in @ESMO_Open. Comparable long-term efficacy, no new safety signals. esmoopen.com/article/S2059-7…

Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02 in @ESMO_Open. irORR 22% and 4% in BTC and PC, respectively, highest in IHC3+ BTC. esmoopen.com/article/S2059-7…

Intratumoral Fusobacterium species and survival in resectable colorectal cancer: a multicenter cohort study in @ESMO_Open. Fusobacterium spp presence identifies CRC with aggressive biology, immunesuppression and reduced adjuvant CT benefit. esmoopen.com/article/S2059-7…

Comparative efficacy of perioperative systemic therapies for MIBC: a network meta-analysis of randomized trials in @ESMO_Open. Improved OS with EV/GC + durva vs GC. Although indirect comparative estimates, EV ranks highest across OS, EFS, and pCR. esmoopen.com/article/S2059-7…

Superselective intra-arterial CRT for maxillary sinus squamous-cell carcinoma: results from the T4bN0M0 cohort of JCOG1212 in @ESMO_Open. Reproducible procedure with 3-year OS 68.8%. Prevalent high grade AEs: neutropenia & mucositis. esmoopen.com/action/showPdf?…

Datopotamab-DXd vs CT in previously treated inoperable/metastatic HR+ HER2- BC: safety & PROs from the ph3 TROPION Breast01 study in @ESMO_Open.Low grade nausea as most common TRAE. Dato-DXd delayed TTD in GHS/QoL, pain & physical functioning. esmoopen.com/action/showPdf?…

Somatic BRCA alterations in BC are associated with distinct biological & clinical patterns according to germline BRCA status in @ESMO_Open. Genomic patterns in sBRCA+ depend on germline status. Only gBRCA linked to shorter CDK4/6i therapy TTD. esmoopen.com/action/showPdf?…

ERBB2/HER2 landscape & prognostic impact: large-scale, RW analysis across solid cancers in @ESMO_Open. >200,000/80,000 samples for NGS/ IHC. Mut & ampl correlation, with mut associated with higher IHC levels (even w/o ampl). 3+IHC vs 0 = longer survival. esmoopen.com/article/S2059-7…

RT @PTarantinoMD: A common worldwide practice is to give chemo prior to ET to patients with untreated HR+ MBC. Multiple randomized studies…

Avelumab 1st line maintenance for advanced UC: long-term outcomes from the JAVELIN Bladder 100 trial in pts with high BMI or diabetes mellitus in @ESMO_Open. OS advantage even in these subgroups, HR consistent with the general enrolled population. esmoopen.com/article/S2059-7…

Anti-EGFR-based maintenance vs stop and go in patients with left-sided, non-MSI-H, RAS/BRAF-wt metastatic CRC: individual patient data pooled analysis in @ESMO_Open. No significant differences in OS & time to failure of strategy between strategies. esmoopen.com/article/S2059-7…

1st line ET plus palbociclib vs standard mono-CT in high-risk HR+ /HER2- metastatic BC and indication for CT: primary results from the randomized phase IV PADMA study in @ESMO_Open.ET+Palbociclib improved TTF and PFS, with higher hematological toxicity. esmoopen.com/article/S2059-7…

Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal mts: a large-scale multicenter retrospective study (FURMO-LM) in @ESMO_Open. Potential of combination therapies in this difficult population. esmoopen.com/article/S2059-7…

Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer in @ESMO_Open. No benefit of scalp cooling in terms of hair preservation or quality of life.G2 alopecia primary reason for scalp cooling discontinuation. esmoopen.com/article/S2059-7…

Safety analyses of the INAVO120 randomised ph III trial of inavolisib or placebo with palbociclib–fulvestrant in pts with PIK3CA-mutated, HR+, HER2-, endocrine-resistant advanced BC in @ESMO_Open. Consistent, manageable & tolerable safety profile. esmoopen.com/article/S2059-7…

Impact of treatment discontinuation among patients with MSI or MRD metastatic CRC treated with immune checkpoint inhibitors in @ESMO_Open. Early discontinuation of ICIs in patients without progression did not compromise PFS or OS esmoopen.com/article/S2059-7…

First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies in @ESMO_Open. Most common TRAES: IRRs (n:14; 7 of G3), pyrexia, myalgia, rash. SD as best response in 39.3% of pts. esmoopen.com/article/S2059-7…